Effect of hydroxypropyl beta cyclodextrin complexation on aqueous solubility, stability, and corneal permeation of acyl ester prodrugs of ganciclovir

AAPS PharmSciTech

Volumn 4, Issue 3, 2003, Pages

  Tirucherai, Giridhar S ^a,b   Mitra, Ashim K ^a  

^a UNIVERSITY OF MISSOURI KANSAS CITY   (United States)

^b IQVIA   (United States)

Author keywords

Aqueous diffusion layer; Cornea; Hydroxypropyl beta cyclodextrin; Prodrugs; Transport

Indexed keywords

2 HYDROXYPROPYL BETA CYCLODEXTRIN; BUFFER; CHOLINESTERASE; ESTER DERIVATIVE; GANCICLOVIR; GANCICLOVIR DERIVATIVE; GANCICLOVIR DIBUTYRATE; GANCICLOVIR DIPROPIONATE; GANCICLOVIR MONOACETATE; GANCICLOVIR MONOBUTYRATE; GANCICLOVIR MONOPROPIONATE; GANCICLOVIR MONOVALERATE; PHOSPHATE; PRODRUG; UNCLASSIFIED DRUG; 2-HYDROXYPROPYL-BETA-CYCLODEXTRIN; BETA CYCLODEXTRIN DERIVATIVE; CARBOXYLIC ACID; CYCLODEXTRIN; DRUG DERIVATIVE;

ANIMAL CELL; ANIMAL TISSUE; AQUEOUS SOLUTION; ARTICLE; COMPLEX FORMATION; CONTROLLED STUDY; CORNEA CELL; DIFFUSION; DRUG DELIVERY SYSTEM; DRUG HYDROLYSIS; DRUG PENETRATION; DRUG SOLUBILITY; DRUG SOLUTION; DRUG STABILITY; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TRANSPORT; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IN VITRO STUDY; LIPOPHILICITY; MALE; MATHEMATICAL COMPUTING; NONHUMAN; PH; RABBIT; ANIMAL; CHEMISTRY; CORNEA; DRUG EFFECT; METABOLISM; PERMEABILITY; SOLUBILITY;

ANIMALS; BETA-CYCLODEXTRINS; CARBOXYLIC ACIDS; CHEMISTRY, PHARMACEUTICAL; CORNEA; CYCLODEXTRINS; DRUG STABILITY; GANCICLOVIR; MALE; PERMEABILITY; PRODRUGS; RABBITS; SOLUBILITY;

EID: 23144451233     PISSN: 15309932     EISSN: 15309932     Source Type: Journal    
DOI: 10.1208/pt040345     Document Type: Article

References (32)

1. Snoeck R, Schols D, Andrei G, Neyts J, De Clercq E. Antiviral activity of anti-cytomegalovirus agents (HPMPC, HPMPA) assessed by a flow cytometric method and DNA hybridization technique. Antiviral Res. 1991;16:1-9.
2. Smee DF, Martin JC, Verheyden JP, Matthews TR. Antiherpesvirus activity of the acyclic nucleoside 9-(1,3-dihydroxy-2-propoxymethyl)guanine. Antimicrob Agents Chemother. 1983;23:676-682.
3. Naito T, Nitta K, Kinouchi Y, Shiota H, Mimura Y. Effects of 9-(1,3-dihydroxy-2-propoxymethyl)guanine (DHPG) eye drops and cyclosporine eye drops in the treatment of herpetic stromal keratitis in rabbits. Curr Eye Res. 1991;10(suppl):201-203.
4. Hoh HB, Hurley C, Claoue C, Viswalingham M, Easty DL, Goldschmidt P, Collum LM. Randomised trial of ganciclovir and acyclovir in the treatment of herpes simplex dendritic keratitis: a multicentre study. Br J Ophthalmol. 1996;80:140-143.
5. Spector SA, McKinley GF, Lalezari JP, Samo T, Andruczk R, Follansbee S, Sparti PD, Havlir DV, Simpson G, Buhles W, Wong R, Stempien M. Oral ganciclovir for the prevention of cytomegalovirus disease in persons with AIDS. Roche Cooperative Oral Ganciclovir Study Group. N Engl J Med. 1996;334:1491-1497.
6. Tirucherai GS, Dias C, Mitra AK. Corneal Permeation of Ganciclovir: Mechanism of Ganciclovir Permeation Enhancement by Acyl Ester Prodrug Design. J Ocul Pharmacol Ther. 2002;18:535-548
7. Macha S, Mitra AK. Ocular disposition of ganciclovir and its monoester prodrugs following intravitreal administration using microdialysis. Drug Metab Dispos. 2002;30:670-675.
8. Yaksh TL, Jang JD, Nishiuchi Y, Braun KP, Ro SG, Goodman M. The utility of 2-hydroxypropyl-beta-cyclodextrin as a vehicle for the intracerebral and intrathecal administration of drugs. Life Sci. 1991;48:623-633.
9. Usayapant A, Karara AH, Narurkar MM. Effect of 2-hydroxypropyl-beta-cyclodextrin on the ocular absorption of dexamethasone and dexamethasone acetate. Pharm Res. 1991;8:1495-1499.
10. Loftsson T, Frithriksdottir H, Thorisdottir S, Stefansson E, Sigurthardottir AM, Guthmundsson O, Sigthorsson T. 2-hydroxypropyl-beta-cyclodextrin in topical carbonic anhydrase inhibitor formulations. Eur J Pharm Sci. 1994;1:175-180.
11. Jarho P, Urtti A, Jarvinen K, Pate DW, Jarvinen T. Hydroxypropyl-beta-cyclodextrin increases aqueous solubility and stability of anandamide. Life Sci. 1996;58: PL 181-185.
12. Loftsson T, Jarvinen T. Cyclodextrins in ophthalmic drug delivery. Adv Drug Deliv Rev. 1999;36:59-79.
13. Loftsson T, Stefansson E, Kristensson JK, Fridriksdottir, H, Sverrisson T, Gudmondsdottir G, Thorisdottir S. Topically effective acetazolamide drop solution in man. Pharm Sci. 1996;6:277-279.
14. Gao H, Mitra AK. Regioselective synthesis of various prodrugs of ganciclovir. Tetrahedron Lett. 2000;41:1131-1136.
15. Higuchi T, Connors KA. "Phase-Solubility Techniques" In Advances in Analytical Chemistry and Instrumentation. New York: Reilly CN; 1965:117-212
16. Tak RV, Pal D, Gao H, Dey S, Mitra AK. Transport of acyclovir ester prodrugs through rabbit cornea and SIRC-rabbit corneal epithelial cell line. J Pharm Sci. 2001;90:1505-1515.
17. Cho MJ, Chen FJ, Huczek DL. Effects of inclusion complexation on the transepithelial transport of a lipophilic substance in vitro. Pharm Res. 1995;12:560-564.
18. Albers E, Muller BW. Complexation of steroid hormones with cyclodextrin derivatives: substituent effects of the guest molecule on solubility and stability in aqueous solution. J Pharm Sci. 1992;81:756-761.
19. Dias CS, Anand BS, Mitra AK. Effect of mono- and diacylation on the ocular disposition of ganciclovir: physicochemical properties, ocular bioreversion, and antiviral activity of short chain ester prodrugs. J Pharm Sci. 2002;91:660-668.
20. Loftsson T, Brewster ME. Pharmaceutical applications of cyclodextrins. 1. Drug solubilization and stabilization. J Pharm Sci. 1996;85:1017-1025.
21. Mielcarek J. Photochemical stability of the inclusion complexes formed by modified 1,4-dihydropyridine derivatives with beta-cyclodextrin. J Pharm Biomed Anal. 1997;15: 681-686.
22. Narurkar MM, Mitra AK. Prodrugs of 5-iodo-2′-deoxyuridine for enhanced ocular transport. Pharm Res. 1989;6:887-891.
23. Jarho P, Jarvinen K, Urtti A, Stella VJ, Jarvinen T. Modified beta-cyclodextrin (SBE7-beta-CyD) with viscous vehicle improves the ocular delivery and tolerability of pilocarpine prodrug in rabbits. J Pharm Pharmacol. 1996;48:263-269.
24. Suhonen P, Jarvinen T, Lehmussaari K, Reunamaki T, Urtti A. Ocular absorption and irritation of pilocarpine prodrug is modified with buffer, polymer, and cyclodextrin in the eyedrop. Pharm Res. 1995;12:529-533.
25. Pauletti GM, Gangwar S, Wang B, Borchardt RT. Esterase-sensitive cyclic prodrugs of peptides: evaluation of a phenylpropionic acid promoiety in a model hexapeptide. Pharm Res. 1997;14:11-17.
26. Bodor NS, Huang MJ, Watts JD. Theoretical studies on the structures of natural and alkylated cyclodextrins. J Pharm Sci. 1995;84:330-336.
27. Masson M, Loftsson T, Masson G, Stefansson E. Cyclodextrins as permeation enhancers: some theoretical evaluations and in vitro testing. J Control Release. 1999;59:107-118.
28. Higuchi T. Physical chemical analysis of percutaneous absorption process from creams and ointments. J Soc Cosmet Chem. 1960;11:85-97.
29. Inatomi T, Spurr-Michaud S, Tisdale AS, Gipson IK. Human corneal and conjunctival epithelia express MUC1 mucin. Invest Ophthalmol Vis Sci. 1995;36:1818-1827.
30. Hidalgo IJ, Hillgren KM, Grass GM, Borchardt RT. Characterization of the unstirred water layer in Caco-2 cell monolayers using a novel diffusion apparatus. Pharm Res. 1991;8:222-227.
31. Wikman A, Karlsson J, Carlstedt I, Artursson P. A drug absorption model based on the mucus layer producing human intestinal goblet cell line HT29-H. Pharm Res. 1993;10:843-852.
32. Ohvo H, Slotte JP. Cyclodextrin-mediated removal of sterols from monolayers: effects of sterol structure and phospholipids on desorption rate. Biochemistry. 1996;35:8018-8024.